Form 4: Jazz Pharmaceuticals EVP Sells Shares in Open Market Transaction

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, sold 3,700 ordinary shares at an average price of $123.41 on November 8, 2024.

Summary

• Neena M Patil, an Executive Vice President and Chief Legal Officer at Jazz Pharmaceuticals, sold 3,700 ordinary shares of the company on November 8, 2024.
• The shares were sold at a weighted average price of $123.41, with individual transaction prices ranging from $123.31 to $123.51.
• Following the transaction, Ms. Patil directly owns 33,048 ordinary shares of Jazz Pharmaceuticals.
• This total includes 119 shares acquired on May 31, 2024, through an Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document is a neutral report of an insider stock sale, which is a routine event. There is no indication of positive or negative sentiment.

Industry Context

This is a routine disclosure of an insider stock sale, which is common for executives of publicly traded companies. It does not indicate any specific trend or issue within the pharmaceutical industry.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation and portfolio management for executives in publicly traded companies, including those in the pharmaceutical sector.
• These transactions are typically disclosed via SEC Form 4 filings, as seen here, and are a standard practice across the industry.
• Comparable companies such as AbbVie, Amgen, and Gilead also have executives who regularly engage in similar stock transactions.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's overall performance.

Key Dates

Keywords

Jazz Pharmaceuticals, insider trading, share sale, executive, stock transaction, Neena M Patil